Neumora Stock

neumoratx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $612.4MM

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing neuroscience drugs.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Neumora before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Neumora before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About Neumora’s Stock

Can you buy Neumora’s stock?
You can no longer buy Neumora’s stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
Can you sell Neumora’s stock?
You can no longer sell stock of Neumora on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
What is Neumora’s stock price?
The stock price of Neumora is $14.66 as of 1/18/24.
What is Neumora’s stock ticker symbol?
The ticker symbol of Neumora is NMRA.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.


SoftBank-backed Neumora seeks $2.74 billion valuation in US IPO
Neumora Therapeutics, backed by Amgen (AMGN.O) and Japan's SoftBank (9984.T), is seeking a valuation of up to $2.74 billion in its U.S. initial public offering, as the biopharmaceutical company looks to ride a revival in stock market listings.
Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases
Neumora Therapeutics, Inc. (Neumora), a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, announced its launch today. Neumora was founded as a response to the lack of targeted, effective medicines for brain diseases and the high failure rate that has plagued neuroscience drug development for decades.
Updated on: Jun 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.